[HTML][HTML] Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open …
Summary Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective
agent that enhances intracellular energy metabolism and reduces oxidative stress. The …
agent that enhances intracellular energy metabolism and reduces oxidative stress. The …
[HTML][HTML] Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open …
S Vucic, P Menon, W Huynh, C Mahoney, KS Ho… - eClinicalMedicine, 2023 - Elsevier
Summary Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective
agent that enhances intracellular energy metabolism and reduces oxidative stress. The …
agent that enhances intracellular energy metabolism and reduces oxidative stress. The …
[HTML][HTML] Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open …
S Vucic, P Menon, W Huynh, C Mahoney, KS Ho… - …, 2023 - ncbi.nlm.nih.gov
Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label …
S Vucic, P Menon, W Huynh, C Mahoney, K Ho… - …, 2023 - europepmc.org
Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label …
S Vucic, P Menon, W Huynh, C Mahoney… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label …
S Vucic, P Menon, W Huynh, C Mahoney, KS Ho… - …, 2023 - europepmc.org
Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …
enhances intracellular energy metabolism and reduces oxidative stress. The phase 2 …